☆ 4.6 Article

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

PLOS ONE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice

Yuka Hayakawa et al.

Summary: The study examined the efficacy and safety of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma based on different treatment lines, showing better clinical outcomes in 1st-line therapy. An early AFP response at 6 weeks could serve as a predictor of disease progression.

INVESTIGATIONAL NEW DRUGS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma

Kazuki Maesaka et al.

Summary: This study compared the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib as primary systemic chemotherapy for HCC. The results showed that atezolizumab plus bevacizumab had a significantly longer progression-free survival and lower rates of adverse events compared to lenvatinib.

HEPATOLOGY RESEARCH (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice

Takaaki Tanaka et al.

Summary: There was no significant difference in the best response between CP-A and -B patients treated with Atez/Bev. Analysis showed that CP-A patients had better progression-free survival (PFS) and overall survival (OS) rates compared to CP-B patients. The median PFS and OS were also significantly different between different Child-Pugh score (CPS) groups and modified albumin-bilirubin grade (mALBI) groups.

HEPATOLOGY RESEARCH (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

Karla A. Lee et al.

Summary: An analysis of metagenomic sequencing of stool samples reveals the association between gut microbiome and response to immune checkpoint blockade therapy in melanoma patients. However, there is limited consistency in the microbiome-based signatures across different populations. Future studies should consider larger sample sizes and examine the complex interplay between clinical factors and the gut microbiome.

NATURE MEDICINE (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Josep M. Llovet et al.

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy

Vyara Matson et al.

Summary: The commensal microbiota plays a role in regulating various physiological processes, including affecting cancer immunotherapy either positively or negatively. Studies have shown that different microbes may have distinct impacts on immunotherapy efficacy, leading to clinical trials and microbiome-based therapeutic interventions.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Jordi Bruix et al.

Summary: Significant advances have been made in the systemic treatment of hepatocellular carcinoma in the last 5 years, with new drugs and treatment strategies emerging. Prolonged survival exceeding 2 years is expected in most patients, and selecting the right medication based on patient characteristics and preferences is crucial for sound therapeutic decisions.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Christine N. Spencer et al.

Summary: The study suggests that dietary fiber intake is associated with significantly improved progression-free survival in melanoma patients receiving ICB treatment, especially without the use of probiotics. Preclinical studies demonstrate that a low-fiber diet or probiotics can impair the treatment response to anti-PD-1 therapy, leading to a lower frequency of interferon-gamma-positive cytotoxic T cells in the tumor microenvironment.

SCIENCE (2021)

添加到收藏夹

Article Oncology

The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression

Nobuaki Ochi et al.

Summary: The study showed that the impact of ATB use on the efficacy of ICIs in NSCLC patients depends on the level of PD-L1 expression. Patients with PD-L1 expression >50% who received ATBs had significantly shorter PFS and OS, while there was no significant impact on patients with PD-L1 expression <50%.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Review Oncology

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Masatoshi Kudo et al.

Summary: The Clinical Practice Manual for Hepatocellular Carcinoma is based on evidence and expert consensus, focusing on pathology, diagnosis, and treatment. Different from the JSH Clinical Practice Guidelines, this manual emphasizes practicality and is written by a panel of experts from the JSH.

LIVER CANCER (2021)

添加到收藏夹

Article Oncology

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini et al.

Summary: The study reveals the negative impact of antibiotics (ATB) on pembrolizumab monotherapy outcomes in NSCLC, while corticosteroids and proton pump inhibitors (PPIs) may worsen baseline performance status. These findings highlight the underlying immune-modulatory effects of these concomitant medications.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Medicine, General & Internal

The association between CD8+tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis

Feng Li et al.

Summary: The study found that high CD8+ TILs were significantly associated with better overall survival, progression-free survival, and objective response rate in cancer patients treated with ICIs. High CD8+ TILs predicted treatment outcomes across different cancers and treatment types.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Oncology

Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma

Petros Fessas et al.

Summary: The study found that the use of antibiotics (ATB) in the 30 days before or after initiation of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) may improve the efficacy of immunotherapy, independent of disease and treatment-related features. Further investigation into the immune microbiologic determinants of response to ICI in HCC is warranted.

LIVER CANCER (2021)

添加到收藏夹

Article Oncology

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

M. Chalabi et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Urology & Nephrology

Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab

Ashley M. Hopkins et al.

EUROPEAN UROLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

Lukas F. Mager et al.

SCIENCE (2020)

添加到收藏夹

Article Oncology

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

John D. Gordan et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

Atsushi Hiraoka et al.

LIVER CANCER (2019)

添加到收藏夹

Article Multidisciplinary Sciences

A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

Takeshi Tanoue et al.

NATURE (2019)

添加到收藏夹

Review Oncology

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis

Steve Lu et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma

Yi Zheng et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

David J. Pinato et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

V. Gopalakrishnan et al.

SCIENCE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy et al.

SCIENCE (2018)

添加到收藏夹

Article Oncology

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

L. Derosa et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

Vyara Matson et al.

SCIENCE (2018)

添加到收藏夹

Article Medicine, Research & Experimental

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Antibiotic-Induced Changes in the Intestinal Microbiota and Disease

Simone Becattini et al.

TRENDS IN MOLECULAR MEDICINE (2016)

添加到收藏夹

Article Oncology

Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma

Qian-Kun Xie et al.

ONCOIMMUNOLOGY (2016)

添加到收藏夹

Article Oncology

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade

Philip J. Johnson et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Marie Vetizou et al.

SCIENCE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Naiyer A. Rizvi et al.

SCIENCE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh et al.

NATURE (2014)

添加到收藏夹

Review Gastroenterology & Hepatology

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

Riccardo Lencioni et al.

SEMINARS IN LIVER DISEASE (2010)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.